MAPT and Alzheimer disease: In keeping with the NIA-AA research framework (Jack et al., 2018), our innovative and timely project will distinguish AD symptomology (presence of mild cognitive impairment) from AD pathology (Aβ accumulation), while also applying the AT (N) classification system [Aβ (A), tau (T), and neurodegeneration (N)] to attain more direct assessment of neuropathologic changes.